DHA-clozapine (tentative trade name Clozaprexin) is an atypical antipsychotic drug candidate that was created and originally tested by chemists at Protarga, a small pharmaceutical in Pennsylvania, and scientists at Harvard University.
|Chemical and physical data|
|Molar mass||637.30 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Protarga was purchased by Luitpold Pharmaceuticals in 2003 and development was discontinued in 2007.
- "DHA-clozapine". AdisInsight. Retrieved 17 March 2017.
- Rosack, Jim (4 May 2001). "Targaceuticals Point Way To Developing Safer Drugs". Psychiatric News. doi:10.1176/pn.36.9.0036.
- Baldessarini, R.; Campbell, A.; Webb, N. L.; Swindell, C. S.; Flood, J. G.; Shashoua, V. E.; Kula, N. S.; Hemamalini, S; Bradley, M. O (200). "Fatty Acid Derivatives of Clozapine Prolonged Antidopaminergic Activity of Docosahexaenoylclozapine in the Rat". Neuropsychopharmacology. 2 (1): 55–65. doi:10.1016/S0893-133X(00)00173-1. PMID 11106876.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|